Willy Adames receives PRP injection in elbow, may be done for 2025

Willy Adames received a platelet-rich plasma injection in his elbow and may be done for the 2025 season, the Giants announced Thursday.

The club did not specify which elbow, the nature of the underlying injury, or a timetable for Adames' return. The announcement leaves open the possibility that the shortstop could play again this year, but the phrasing suggests San Francisco is preparing for his absence through the final month.

What happened

Adames underwent the PRP procedure, a regenerative treatment in which a concentrated dose of the player's own platelets is injected into damaged tissue to accelerate healing. The Giants disclosed the injection and the potential outcome but offered no further detail on the injury itself or when it occurred.

Platelet-rich plasma injections are common in baseball for ligament and tendon issues, particularly in the elbow, though they are also used for muscle strains and joint inflammation. The treatment typically requires a period of rest before the player can resume throwing or swinging, and the recovery timeline varies widely depending on the severity of the underlying damage.

The club's language—"may be done," not "is done"—preserves a sliver of uncertainty, but with five weeks remaining in the regular season and the Giants eliminated from the division race, the operational reality is that Adames is unlikely to return unless the injury proves less serious than the announcement implies.

Why it matters

Adames arrived in San Francisco as the centerpiece of the club's winter spending, brought in to anchor the middle infield and provide offensive consistency. Losing him for the final stretch of a lost season is not a competitive blow—the club sits 26.5 games back in the National League West—but it is a concerning development for a player whose durability has been a hallmark of his career.

An elbow issue significant enough to require a PRP injection and potentially end his season raises questions about his offseason program and his readiness for spring training, though the club has not suggested the injury will carry into 2026.

For the Giants, the immediate concern is roster construction over the final month. With Adames sidelined, the club will need to lean on its depth options to cover shortstop. The injury also complicates any evaluation of the infield's chemistry heading into next season, as Adames was expected to be the defensive and offensive centerpiece of that group.

Where the club stands

The Giants entered Thursday with a 59-84 record, fourth in the National League West and 26.5 games behind the division leader. They are 16.0 games out of the final Wild Card spot and have been eliminated from the division race. San Francisco has won one game in a row.

The club opens a three-game series against the Arizona Diamondbacks on Friday at Oracle Park, with Blade Tidwell scheduled to face Kohl Drake. Saturday's doubleheader features Matt Wilkinson against Merrill Kelly in the first game and Yunior Marte against Mitch Bratt in the nightcap.

With five weeks remaining, the Giants are playing out the string in a season that has been defined by underperformance across the roster. The club entered the year with playoff expectations after an aggressive winter, but injuries, inconsistent pitching, and a punchless offense have left them well out of contention by late August.

What we don't know yet

The Giants did not disclose which elbow received the injection, the specific diagnosis, or when the injury occurred. It is unclear whether Adames has been playing through discomfort for an extended period or whether the issue arose recently and worsened quickly enough to require immediate intervention.

The club also did not provide a formal timetable for his return, leaving open the question of whether he will be available for any games in September. The phrase "may be done" suggests the organization is operating under the assumption that he will not play again this year, but the lack of a definitive shutdown leaves room for a late-season return if the elbow responds well to the injection and rest.

There is no indication yet of whether the injury will require offseason treatment beyond the PRP procedure. The club has not commented on Adames' availability for winter baseball or his expected readiness for spring training.

What to watch

The Giants will need to clarify Adames' status in the coming days, particularly if he is placed on the injured list. A formal IL stint would confirm that the club does not expect him back in the near term and would open a roster spot for another infielder or position player.

If Adames does not return this season, the focus will shift to his offseason recovery and whether the elbow issue requires any additional procedures. PRP injections are often a first step in treating ligament or tendon damage, and if the underlying injury does not heal fully, more invasive options could be on the table.

For now, the Giants will turn to their depth options at shortstop and continue to evaluate the roster with an eye toward 2026. The club will need to determine whether it has credible backup options at the position or whether further infield help is required this winter.

The announcement also raises broader questions about the Giants' medical and training staff, as this is the latest in a series of injuries that have derailed the club's season. While no single injury can be attributed to organizational failure, the cumulative toll of missed time across the roster has been a defining feature of a disappointing year in San Francisco.